Intravenous glutamine does not modify leucocyte count but shortens duration of mucositis after bone marrow transplant
DOI:
https://doi.org/10.19230/2251Keywords:
mucositis, glutamine, bone marrow transplant, chemotherapy, radiotherapyAbstract
Rationale: Intravenous administration of Glutamine dipeptides (Gln) has been proposed as treatment of oral mucositis following a bone marrow transplant (BMT).
Objective: To establish the effects of intravenous Gln supplementation upon the severity of oral mucositis after BMT.
Study design: Retrospective, analytical.
Study serie: Records from 25 patients (Males: 56.0%; BMT cause: Leukemia: 64.0%) who developed oral mucositis (Grades III – IV: 48.0%) after BMT (Autologous: 44.0%) at the "Juan Tanca Marengo" Hospital (Guayaquil, Ecuador) between 2009 – 2017.
Glutamine source: Dipeptiven©®: 13 grams of Gln suspended in 100 milliliters of a 20% solution of the alanine-glutamine dipeptide (Fresenius-Kabi©®, Germany).
Materials and Methods: Gln-treated patients received 3(4.0% of the treatment leg), 5 (20.0%); 6 (12.0%); 7 (48.0%); or 10 (16.0%) doses of the dipeptide until resolution of the symptoms. Impact of Gln was estimated from changes observed in the severity and duration of mucositis, white blood cell counts, and body weight regarding 25 non-Gln treated patients (Males: 68.0%; Leukemias: 32.0%; Autologous graft: 68.0%; Grade III – IV mucositis: 48.0%).
Results: Intravenously-administered Gln shortened duration of oral mucositis: Gln-Treated: 12.5 ± 5.1 days vs. Non-Gln Treated: 21.3 ± 17.8 days (p < 0.05). Also, intravenous Gln marginally ameliorated loss of body weight: Gln-Treated -4.5 ± 5.5% vs. Non-Gln Treated: -7.5 ± 5.7% (p = 0.07).
Conclusions: Intravenous Gln administration shortens duration of oral mucositis following BMT. Gln effect might be translated to a lesser weight loss in patients with oral mucositis.
Downloads
References
Ferreiro J, García JL, Barceló R, Rubio I. Quimioterapia: Efectos secundarios. Gaceta Médica Bilbao 2003;100:69-74.
Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Principios de Medicina interna [de] Harrison. Volumen 1. Décimo-octava Edición. México DF: 2012. McGraw-Hill Interamericana. Pp 692.
Araújo SNM, Luz MHBA, da Silva GRF, Andrade EMLR, Nunes LCC, Moura RO. Cancer patients with oral mucositis: Challenges for nursing care. Rev Latino-Americana Enfermagem 2015;23:267-74.
Ngeow WC, Chai WL, Zain RB. Management of radiation therapy-induced mucositis in head and neck cancer patients. Part I: Clinical significance, pathophysiology and prevention. Oncol Rev 2011;2:102-13.
Leung HWC, Chan ALF. Glutamine in alleviation of radiation-induced severe oral mucositis: A meta-analysis. Nutr Cancer 2016;68:734-42.
Chaveli B, Bagán JV. Treatment of oral mucositis due to chemotherapy. J Clin Exp Dentistry 2016;8(2), e201-e209.
Pabón A, Camacho S. La mucositis oral, una complicación frecuente en pacientes con tratamiento oncológico: Revisión de literatura. Rev Estomatol Salud 2012;20(1):39-44.
Santana Porbén S. Metabolismo tisular de los sustratos. En: Nutrición enteral y Parenteral [Editores: Anaya Prado R, Arenas Moya D]. Segunda Edición. Editorial McGraw Hill-Interamericana. Ciudad México: 2014.
Chang YH, Yu MS, Wu KH, Hsu MC, Chiou YH, Wu HP; et al. Effectiveness of parenteral glutamine on methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. Nutr Cancer 2017;69:746-51.
Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T; et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: A double-blind, randomized, placebo-controlled trial. Oncology Reports 2015;33:33-9.
Herrera AD, Alhambra MR, Manzano G, Molina MJ, Calañas A, Bahamondez R; et al. Use of glutamine in total parenteral nutrition of bone marrow transplant patients. Nutrición Hospitalaria [España] 2015;31:1620-4.
López D. Eficacia de la glutamina como agente protector en la mucositis oral y radiodermitis inducida por la radioterapia o radio/quimioterapia en el tratamiento del cáncer de cabeza y cuello. Universidad de Sevilla. Sevilla [España]: Septiembre del 2015.
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F; et al. ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition 2017;36:11-48.
Santana Porbén S, Martínez Canalejo H. Manual de Procedimientos Bioestadísticos. Segunda Edición. EAE Editorial Académica Española. ISBN-13: 9783659059629. ISBN-10: 3659059625. Madrid: 2012.
Chattopadhyay S, Saha A, Azam M, Mukherjee A, Sur PK. Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: A prospective randomized study. South Asian J Cancer 2014;3:8-12.
Gil Hernández A. Nuevos nutrientes en nutrición enteral y parenteral. En: Tratado de Nutrición. Segunda Edición. Volumen 4. Editorial Panamericana. Madrid: (2010). pp. 205-232.
Marsé P, Pérez J. Glutamina en el paciente estresado. NutriInfo 2013;1-10.
Rajendram R, Preedy VR, Patel VB. Glutamine in clinical nutrition. Humana Press. New York: 2015.
Yamaguchi N, Suzuki Y, Mahbub MH, Takahashi H, Hase R, Ishimaru Y; et al. The different roles of innate immune receptors in inflammation and carcinogenesis between races. Environm Health Prevent Med 2017;22(1):70. Disponible en: https://doi.org/10.1186/s12199-017-0678-8. Fecha de última visita: 13 de Agosto del 2017.
Lin M, Zhang B, Yu C, Li J, Zhang L, Sun H; et al. L-glutamate supplementation improves small intestinal architecture and enhances the expressions of jejunal mucosa amino acid receptors and transporters in weaning piglets. Plos One 2014;9(11):e111950. Disponible en: https://doi.org/10.1371/journal.pone.0111950. Fecha de última actualización: 14 de Agosto del 2017.
Jiang JW, Zheng SS, Xue F, Gao LH, Jiang GP, Xie HY. Enteral feeding of glycyl-glutamine dipeptide improves the structure and absorptive function of the small intestine after allogenetic liver transplantation in rats. Hepatobil Pancreat Dis Int 2006;5:199-204.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
